@imback, Thanks, the "Least Burdensome Approach" link is for medical devices, but I agree we're certainly in a regulatory climate where the FDA is cooperating to expedite things.
I noticed this evening Humanigen's lenzilumab was chosen by NIAID for a "Big Effect Trial" to be done using it in combination with remdesivir. It was on my May 21 list where I expressed concern it might be slightly ahead of us in phase 3. Looks like NIAID liked some preliminary results.
Let's see if something similar might happen with rem-L.
Investors in MSB / MESO competitors research us, page-48
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |